Trial Profile
A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Vanda Pharmaceuticals
- 06 Aug 2015 Results of two trials (SET and RESET) published online in the Lancet.
- 05 Aug 2015 According to a Vanda Pharmaceuticals media release, this and SET trial led to approval with the European marketing authorization for Hetlioz.
- 05 Aug 2015 Results published in the Vanda Pharmaceuticals media release.